PCC Rokit (PCR) Q3 2024 earnings summary

Executive summary

• Revenue for 1-3Q 2024 was 1,460.1 million PLN, down 21% year-over-year, mainly due to a sharp decline in the Chlorine Derivatives segment.

• Consolidated EBITDA for 1-3Q 2024 was 209.6 million PLN, down 46% year-over-year.

• Net profit for 1-3Q 2024 was 38.7 million PLN, a 79% decrease compared to 1-3Q 2023.

• Q3 2024 results were notably weaker than in the previous two quarters, impacted by a planned maintenance shutdown.

• Key investments completed include a new sodium hypochlorite plant and continued expansion of membrane electrolysis capacity.

Financial highlights

• Gross margin decreased to 20.0% from 25.5% year-over-year.

• EBITDA margin dropped to 14.4% from 20.9% year-over-year.

• Net profit margin fell to 2.6% from 10.0% year-over-year.

• Operating cash flow was 190.1 million PLN in 1-3Q 2024, down from 367.3 million PLN in 1-3Q 2023.

• Capital expenditures totaled 91.7 million PLN in the first three quarters.

Outlook and guidance

• Market conditions remain challenging, especially in construction and chemical sectors, with ongoing market volatility and macroeconomic uncertainty.

• Uncertainty persists regarding future prices for caustic soda and sodium hydroxide.

• The company anticipates maintaining positive operating cash flow and sufficient liquidity to cover investments and debt service.

• Ongoing investment projects continue, including a new universal plant in Brzeg Dolny.